Drug intelligence / Profile preview

cobicistat + crizotinib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **cobicistat**, a strong CYP3A inhibitor used primarily to enhance the effects of certain HIV medications, and **crizotinib**, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) and other conditions. Cobicistat can increase the plasma concentrations of crizotinib by inhibiting its metabolism via CYP3A, potentially enhancing its efficacy but also increasing the risk of adverse effects.

Targets

CYP3A4 (Cytochrome P450 3A4)MET (Mesenchymal-epithelial transition factor receptor)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)

Beyond the preview

Go deeper on cobicistat + crizotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cobicistat + crizotinib.

Explore the full profile